Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New site-agnostic therapies highlight the importance of genetic testing.
RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.
A new therapy, BLU-667, shows broad antitumor activity against cancers with a variety of RET alterations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.